Avastin, Taking Avastin off-label for breast cancer treatment is essentially government rationing

During Breast Cancer Month Obama’s FDA Ponders Delisting Cancer Drug

By Warner Todd Huston
Wednesday, October 27, 2010

So you have Avastin, a drug used to treat breast cancer that has a record of extending the lives of sufferers for at least five and a half months, http://prescriptions.blogs.nytimes.com/ ... ncer-drug/ and it’s October, the month declared Breast Cancer Awareness Month. http://www.nbcam.org/ If you are the Obama Federal Drug Administration, what do you do? Apparently you look to delist the drug.

This October the FDA is trying to decide to delist Avastin because in keeping with its new Obamacare rationing impulses it has decided Avastin costs too much.

In September the FDA announced that it was going to delay its final decision perhaps until December on whether or not to take Avastin off the market for breast cancer patients. There was no clear indication of just when the decision would be made, but conveniently the decision certainly will be delayed until after the coming elections. As a result President Obama won’t have to worry about taking a drug away from breast cancer patients in the midst of an election cycle.

The calculation of skipping past the elections is hard to ignore.

Senator David Vitter (R, LA) has pointed out the “rationingâ€